Form 8-K - Current report:
SEC Accession No. 0001193125-24-162715
Filing Date
2024-06-17
Accepted
2024-06-17 17:25:01
Documents
13
Period of Report
2024-06-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d786440d8k.htm   iXBRL 8-K 37438
  Complete submission text file 0001193125-24-162715.txt   160464

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA smmt-20240612.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE smmt-20240612_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE smmt-20240612_pre.xml EX-101.PRE 11265
16 EXTRACTED XBRL INSTANCE DOCUMENT d786440d8k_htm.xml XML 3639
Mailing Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025
Business Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025 650-460-8308
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 241049393
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)